Janusinfo är avsedd för läkare och sjukvårdspersonal. Patienter och allmänhet hänvisas till Vårdguiden.



E-tjänster läkemedel
Environment and pharmaceuticals / Environmentally classified pharmaceuticals / C Cardiovascular system

Environmentally classified pharmaceuticals

Two substances may have the same risk values but different PBT values, but the risk assessment can also be different even if the PBT values are the same. When assessing a medication's environmental impact, consideration should be given to both environmental risk and environmental hazard since bioaccumulation and persistence are not included in the risk assessment.

The Swedish Association of the Pharmaceutical Industry conducted the environmental risk assessment, beginning in 2005.

How to read the table

Last updated: 2011-05-11

« New search


C Cardiovascular system

 
 Substance  Risk  PBT  P  B  T  Volume in DDD
C01 Cardiac therapy
glyceryl trinitrate insigni-
ficant		 6 3 0 3 1 410 475 
isosorbide mononitrate cannot be excl 4
N.B.		 3
N.B.		 0 1
N.B.		 7 502 114 
amiodarone cannot be excl 7
N.B.		 3 3 1
N.B.		 169 271 
epinephrine cannot be excl  -  -  -  - 135 685 
digoxin cannot be excl  -  -  -  - 1 883 974 
norepinephrine cannot be excl  -  -  -  - 23 185 
fishoil exempt         C 156 377 
lidocaine insigni-
ficant		 3 3 0 0 69 
C, E 532 449 
disopyramide cannot be excl 4
N.B.		 3
N.B.		 0 1
N.B.		 207 901 
milrinone cannot be excl 4
N.B.		 3 0 1
N.B.		 402 
etilefrine cannot be excl 8
N.B.		 3 3
N.B.		 2
N.B.		 49 477 
alprostadil cannot be excl  -  -  -  - 156 062 
dopamine cannot be excl  -  -  -  - 568 
C02 Antihypertensives
doxazosin cannot be excl 6
N.B.		 3 0 3
N.B.		 1 092 287 
moxonidine insigni- ficant 5 3 0 2 82 921 
hydralazine cannot be excl 6
N.B.		 3 0 3
N.B		 13 650 
clonidine cannot be excl 6
N.B.		 3 0 3
N.B.		 29 730 
methyldopa cannot be excl - - - - - 
C03 Diuretics
furosemide insigni-
ficant		 4 3 0 1 23 504 175 
hydrochlor-
thiazide		 insigni-
ficant		 4
N.B.		 3 0 1
N.B.		 2 923 802 
C 24 226 432 
amiloride cannot be excl 4
N.B.		 3
N.B.		 0 1
N.B.		 361 649 
C 9 737 215 
bendro-
flumethiazide		 cannot be excl 4
N.B.		 3
N.B.		 0 1 6 380 579 
C 188 863 
spironolactone cannot be excl - - - - 2 264 096 
torasemide insigni- ficant 4 3 0 1 59 743 
eplerenone insigni-
ficant		 6 3 0 3 75 785 
bumetanide cannot be excl 4
N.B.		 3
N.B.		 0 1 57 568 
metolazone cannot be excl - - - - 7 359 
C04 Peripheral vasodilators
ginkgo biloba exempt         - 
C05 Vasoprotectives
horse-chestnut exempt         - 
lidocaine insigni-
ficant		 3 3 0 0 69 
C, E 532 449 
hydrocortisone cannot be excl 1
N.B.		 0 0 1
N.B.		 429 014 
C, E 9 858 435 
esculoside cannot be excl - - 0 - - 
framycetin cannot be excl - - 0 - - 
cincocaine cannot be excl - - 3 - - 
heparinoid cannot be excl - - - - - 
prednisolone cannot be excl - - - - 4 732 223 
C07 Beta blocking agents
bisoprolol insigni-
ficant		 4 3 0 1 3 687 610 
metoprolol insigni-
ficant		 4 3 0 1 17 709 170 
C 658 929 
labetalol cannot be excl 6
N.B.		 3
N.B.		 0 3
N.B.		 46 585 
pindolol insigni-
ficant		 4 3 0 1 129 065 
carvedilol insigni-
ficant		 6 3 0 3 804 107 
propranolol moderate 3 0 0 3 1 196 408 
atenolol cannot be excl 4
N.B.		 3
N.B.		 0 1
N.B.		 5 117 184 
sotalol cannot be excl 6
N.B.		 3 0 3
N.B.		 981 631 
esmolol cannot be excl - - - - - 
C08 Calcium channel blockers
amlodipine insigni-
ficant		 6 3
 0 3 20 533 219 
C 97 048 
verapmil insigni-
ficant		 7
N.B.		 3
N.B.
 3 1
N.B.		 823 330 
isradipin insigni-
ficant		 9 3 3 3 218 417 
felodipine low 9 3 3 3 15 568 303 
C 658 929 
diltiazem cannot be excl 4
N.B.		 3 0 1
N.B.		 806 225 
nifedipine cannot be excl 5
N.B.		 3 0 2
N.B.		 313 133 
C09 Agents acting on the renin-angiotensin system
losartan insigni- ficant 3 3 0 0 6 940 342 
C 4 197 058 
ramipril insigni-
ficant		 6
N.B.		 3 3
N.B.		 0 17 245 486 
C 326 098 
enalapril insigni-
ficant		 3
N.B.		 3 0 0
N.B.		 27 659 645 
C 3 940 500 
candesartan cannot be excl 4
N.B.		 3 0 1
N.B.		 15 986 346 
C 3 248 
eprosartan insigni-
ficant		 3 3 0 0 86 114 
C 62 720 
cilazapril insigni- ficant 4 3 0 1 C 3 430 
irbesartan insigni-
ficant		 4 3 0 1 2 076 646 
C 994 672 
valsartan insigni-
ficant		 4 3 0 1 1 677 732 
C 1 359 093 
fosinopril insigni-
ficant		 4
N.B.		 3 0 1
N.B.		 7 333 
telmisartan insigni-
ficant		 5 3 0 2 469 672 
C 171 626 
trandolapril insigni-
ficant		 6
N.B.		 3 0 3
N.B.		 - 
lisonopril cannot be excl 3
N.B.		 3 0 0
N.B.		 980 981 
C 180 088 
captopril cannot be excl 4
N.B.		 3 0 1
N.B.		 507 694
quinapril cannot be excl - - - - 57 312 
C 102 328 
C10 Lipid modifying agents
simvastatin insigni-
ficant		 4 3 0 1 31 587 765 
rosuvastatin insigni- ficant 1 0 0 1 2 693 219 
atorvastatin insigni-
ficant		 4 3 0 1 6 252 461 
fluvastatin insigni-
ficant		 4 3 0 1 30 279 
pravastatin insigni-
ficant		 4 3 0 1 1 157 254 
bezafibrate insigni- ficant 5 3 0 2 116 673 
ezetimibe insigni-
ficant		 6 3 0 3 1 422 200 
fenofibrate insigni-
ficant		 9 3 3 3 143 350 
gemfibrozil low 5 3 0 2 280 345 
cholestyramine cannot be excl 6
N.B.		 3 0 3
N.B.		 112 434 
colestipol cannot be excl -  -  -  -  28 891 
Skriv ut sidan